New combo therapy aims to reignite immune attack on drug-resistant tumors
NCT ID NCT03474497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab). The goal is to see if this triple approach can shrink tumors throughout the body and improve disease control. About 18 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UC Davis Medical Center
Sacramento, California, 95817, United States
-
University of California Davis Medical Center
Sacramento, California, 97817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?